Two months after laying off 20% of its staff, Korro Bio says it has not retreated from its “3-2-1” corporate strategy as it prepares to release interim clinical data on its lead candidate KRRO-110 in ...

A gene-editing delivery system developed by UT Southwestern Medical Center researchers simultaneously targeted the liver and lungs of a preclinical model of a rare genetic disease known as alpha-1 ...

DUBLIN-- (BUSINESS WIRE)--Jun 13, 2025-- The "Alpha-1 Antitrypsin Deficiency Market - A Global and Regional Analysis: Focus on Treatment, Distribution Channel, and Regional Analysis - Analysis and ...

On ASCO Day 3, AstraZeneca is dominant (again), Protagonist Therapeutics and Takeda review blood cancer data, and more.

No-moat Takeda Pharmaceutical is Japan’s leading pharmaceutical company by revenue. While the firm historically focused on the Japan market, management has undertaken an ambitious overhaul to ...

Takeda Announces FY2024 Full Year Results and FY2025 Outlook Reflecting Growth & Launch Products Momentum, Strong Cash Flow Generation and Late-Stage Pipeline Progress ...

AATD is a genetic condition where the body doesn't produce enough of a protective protein, while COPD is typically caused by long-term exposure to irritants like cigarette smoke.

(RTTNews) - Prime Medicine, Inc. (PRME), Tuesday announced the initiation of its preclinical program for the treatment of Alpha-1 Antitrypsin Deficiency or AATD using its proprietary Prime Editing ...